NYSE$OGN
Organon & Co. · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Organon's financial performance remained stable with slight revenue growth, driven by Women's Health and Biosimilars, while Established Brands faced challenges.
Organon reported second-quarter revenue of $1.607 billion, flat year-over-year on an as-reported basis but up 2% ex-FX. Women's Health and Biosimilars showed growth, while Established Brands declined slightly. Net income was $195 million, or $0.75 per diluted share. The company is tracking well to its 2024 objectives.
- Total revenue was $1.607 billion, flat year-over-year but increased 2% ex-FX.
- Women’s Health revenue increased 3% driven by Nexplanon growth.
- Biosimilars revenue grew 22% due to Hadlima uptake.
- Net income was $195 million, or $0.75 per diluted share.
Headline financials
Revenue & EPS history
Organon · Revenue · Quarterly
$1.61B
Revenue by segment
Organon · $1.52B total across 4 segments · Q3 2023
- Established Brands$959M—63.1%
- Women's Health$376M—24.8%
- Biosimilars$144M—9.5%
- Other$40M—2.6%
Forward guidance
Full year 2024 financial guidance is presented on a non-GAAP basis, except revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.9%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-4.8%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+14.4%
Q4 2023
Best reaction
-26.9%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +0.1% | +0.1% | |
| Q4 2025 | -8.2% | -5.3% | -17.4% | |
| Q3 2025 | +14.0% | +11.1% | +5.9% | |
| Q1 2025 | -26.9% | -29.4% | -28.7% | |
| Q4 2024 | +11.0% | +5.3% | +4.1% | |
| Q3 2024 | +0.8% | -8.2% | -11.5% | |
| Q2 2024 | -5.6% | -0.2% | +5.8% | |
| Q1 2024 | +4.1% | +8.3% | +13.3% | |
| Q4 2023 | +14.4% | +13.0% | +11.7% | |
| Q3 2023 | -9.2% | -15.3% | -21.5% | |
| Q2 2023 | +6.2% | +6.2% | -10.7% | |
| Q1 2023 | -7.1% | -12.4% | -18.5% | |
| Q4 2022 | -11.1% | -7.6% | -25.9% | |
| Q3 2022 | -6.1% | -9.1% | +3.0% | |
| Q2 2022 | -3.3% | -3.6% | -12.5% | |
| Q1 2022 | +4.8% | +4.7% | +12.0% | |
| Q4 2019 | +0.8% | -0.3% | -4.9% | |
| Q4 2021 | -0.7% | -1.0% | -3.5% | |
| Q3 2020 | -3.9% | -5.1% | -17.2% | |
| Q3 2021 | -8.0% | -8.4% | -21.5% | |
| Q2 2020 | +3.4% | -2.9% | -1.4% | |
| Q2 2021 | +14.3% | +18.2% | +13.2% | |
| Q4 2020 | -1.5% | +0.7% | +1.6% | |
| Q1 2020 | -1.5% | +0.7% | +1.6% | |
| Q1 2021 | -1.5% | +0.7% | +1.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro